Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on NOVO NORDISK A/S
08/21 NOVO NORDISK A/S : - Share repurchase programme
08/18 NOVO NORDISK A/S : ex-dividend day for interim dividend
08/17 NOVO NORDISK A/S : - Semaglutide superior to dulaglutide on glucose control and ..
08/17 ELI LILLY AND CO (NYSE : LLY) Tanks As Novo Nordisk A/S (ADR) (NYSE:NVO) Diabete..
08/16 NOVO NORDISK A/S : Semaglutide superior to dulaglutide on glucose control and we..
08/16 NOVO NORDISK A/S : Trading in Novo Nordisk Shares by Board Members, Executives a..
08/16 NOVO NORDISK A/S : - Share Repurchase Programme
08/16 NOVO NORDISK A/S : A S - Share repurchase programme
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker -2-
08/15DJWHEN 'NEW AND IMPROVED' FAILS : Insulin Maker Stumbles When Customers Balk
08/15 NOVO NORDISK A/S : Changes in Novo Nordisk Executive Management
08/14 NOVO NORDISK A/S : A S - Trading in shares by board members, executives and asso..
08/14 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
08/14 NOVO NORDISK A/S : - Share repurchase programme
08/10 NOVO NORDISK A/S : Recent Findings from Novo Nordisk Advance Knowledge in Type 2..
08/10 NOVO NORDISK A/S : beats 2Q profit forecasts
08/10 NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives a..
08/10 NOVO NORDISK A/S : may drop US insulin price as Sanofi suffers
08/09DJNOVO NORDISK A/S : Upbeat on Sales Outlook Despite Flat Earnings -- Update
08/09DJNOVO NORDISK A/S : Upbeat on Sales Outlook Despite Flat Second-Quarter Earnings
08/09 NOVO NORDISK A/S : increased reported operating profit by 8% in the first six mo..
08/08 NOVO NORDISK A/S : - Share repurchase programme
08/04NOVO NORDISK A/S : half-yearly earnings release
08/03 NOVO NORDISK A/S : New Data from Novo Nordisk Illuminate Findings in Type 2 Diab..
08/02 NOVO NORDISK A/S : K&L Gates Adds Experienced Health Care Adviser as Washington,..
07/31 NOVO NORDISK A/S : - Share repurchase programme
07/28 NOVO NORDISK A/S : Ministry issues circular on insulin cartridge holders
07/28 NOVO NORDISK A/S : Victoza has been approved in the EU as the only GLP-1 with a ..
07/28 NOVO NORDISK A/S : UK Triathlon Standout Moves Up to Team Novo Nordisk Pro Squad..
07/28 NOVO NORDISK A/S : Victoza Has Been Approved in EU As Only GLP-1 With Label to I..
07/28 NOVO NORDISK A/S : Says European Commission Approves Update To Victoza Label
07/27 NOVO NORDISK A/S : Victoza® has been approved in the EU as the only GLP-1 with a..
07/27 NOVO NORDISK A/S : Victoza® has been approved in the EU as the only GLP-1 with a..
07/27 NOVO NORDISK A/S : Governor Cooper Declares North Carolina 'Ready to Lead' on Gl..
07/27 NOVO NORDISK A/S : UK Triathlon Standout Moves Up to Team Novo Nordisk Pro Squad..
07/24 NOVO NORDISK A/S : - Share repurchase programme
07/24 NOVO NORDISK A/S : Regional drugs supplier firms sign deal to cut cost of drugs
07/24 NOVO NORDISK A/S : Regional supplier in partnership to cut cost of drugs
07/21 GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/20 NOVO NORDISK A/S : Data on Inflammatory Bowel Disease Reported by Researchers at..
07/20 NOVO NORDISK A/S : and Glooko advance their digital health collaboration with la..
07/20 CELGENE : 3 Big Pharma Companies With the Best Projected Return on Investment
07/19 NOVO NORDISK A/S : Global Benzalkonium Chloride Market 2017 By Top Players - FeF..
07/18 RADIUS HEALTH : Appoints Jesper Hiland as President and Chief Executive Officer ..
07/17 RADIUS HEALTH, INC. (NASDAQ : RDUS) Files An 8-K Departure of Directors or Certa..
07/17 NOVO NORDISK A/S : - Share repurchase programme
07/15 NOVO NORDISK A/S : and Glooko launch diabetes management app
07/13 NOVO NORDISK A/S : recalls cartridge holders in certain NovoPen Echo® insulin de..
07/12 NOVO NORDISK A/S : To launch anti-obesity drug in india
07/11 NOVO NORDISK A/S : - Share repurchase programme
07/10 NOVO NORDISK A/S : Team Novo Nordisk Invites Young Athletes With Diabetes to Cam..
07/09 Shire gets injunction against Roche over hemophilia drug
07/06 RESEARCHERS AT NOVO NORDISK REPORT F : Measuring obesity in performance framewor..
07/06 NOVO NORDISK A/S : Patent Issued for Injection Device with Torsion Spring and Ro..
07/06 NOVO NORDISK A/S : issues recall for NovoPen Echo and NovoPen 5 devices
07/06 Statoil ASA (STO) Mix Thrust In Focus with CIT Group Inc. (CIT), Novo Nordisk..
07/06 SANOFI : Sen. Klobuchar Presses Three Pharmaceutical Companies for Action on Hig..
07/05 NOVO NORDISK A/S : supports Chinas pharmaceutical industry
07/05 NOVO NORDISK A/S : Important safety information for people with diabetes using N..
07/05 NOVO NORDISK A/S : supports China’s pharmaceutical industry
07/04 NOVO NORDISK A/S : to Present 35 Abstracts at the International Society on Throm..
07/03 NOVO NORDISK A/S : to Present 35 Abstracts at International Society on Thrombosi..
07/03 NOVO NORDISK A/S : Status regarding Novo Nordisk's holding of its own shares (30..
07/03 NOVO NORDISK A/S : - Share repurchase programme
07/03 NOVO NORDISK A/S : to present 35 abstracts at the International Society on Throm..
07/01 DONG ENERGY : s Asns power plant (782 MW) will phase-out coal
06/29 NOVO NORDISK A/S : Reports Findings in Sulfides (Complete Mapping of Complex Dis..
06/29 NOVO NORDISK A/S : receives positive 17-2 vote from FDA Advisory Committee that ..
06/29 NEW TYPE 2 DIABETES STUDY FINDINGS R : Effects of Benefit...
06/29 DONG ENERGY : finalises bio plans
06/28 DONG Energy - One of the largest power stations in Denmark can phase out coal
06/26 NOVO NORDISK A/S : - Share repurchase programme
06/24 NOVO NORDISK A/S : Announces Headline Results Of Semaglutide
06/24 NOVO NORDISK A/S : Novos Saxenda label to include cardio data
06/24 NOVO NORDISK A/S : reports up to 13.8% weight loss in people with obesity receiv..
1  2  3  4  5  6  7  8  9  10Next
Financials ( DKK)
Sales 2017 113 382 M
EBIT 2017 49 220 M
Net income 2017 38 214 M
Finance 2017 18 480 M
Yield 2017 2,71%
P/E ratio 2017 18,53
P/E ratio 2018 17,26
EV / Sales 2017 4,79x
EV / Sales 2018 4,61x
Capitalization 562 078 M
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 288  DKK
Spread / Average Target 0,70%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S12.45%88 994
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705